The objectives of this review were to determine the effectiveness and safety of a
20 μg/day levonorgestrel releasing intrauterine system (LNG-IUS) in pre- and postmenopausal
women taking adjuvant tamoxifen following breast cancer [
[1]
]. Women were excluded if they had contraindications to the IUS, evidence of recurrent
breast cancer or history of other malignant disease. The primary outcomes considered
were endometrial polyps, hyperplasia or cancer; secondary outcomes were fibroids,
abnormal vaginal bleeding or spotting, and breast cancer recurrence or breast cancer
related death. The analysis was based on four randomised trials that involved 543
pre-and post menopausal women (273 in the treatment arm, 270 controls) with breast
cancer on adjuvant tamoxifen [
- Dominick S.
- Hickey M.
- Chin J.
- Su H.I.
Levonorgestrel intrauterine system for endometrial protection in women with breast
cancer on adjuvant tamoxifen.
Cochrane Database Syst. Rev. 2015; (Art. No.: CD007245. pub3)https://doi.org/10.1002/14651858
2
,
3
,
4
,
5
]. The trials compared endometrial surveillance with the use of the LNG-IUS to endometrial
surveillance alone with a follow up period of 24–60 months.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to MaturitasAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.Cochrane Database Syst. Rev. 2015; (Art. No.: CD007245. pub3)https://doi.org/10.1002/14651858
- Prophylactic use of levonorgestrel-releasing intrauterine system in women with breast cancer treated with tamoxifen: a randomized controlled trial.Obstet. Gynecol. 2013; 121: 943-950
- Prevention of tamoxifen induced endometrial polyps using levonorgestrel releasing intrauterine system: long-term follow-up of a randomised control trial.Gynecol. Oncol. 2009; 114: 452-456
- Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen.Climacteric. 2008; 11: 252-257
- The use of levonorgestrel-releasing intrauterine system in prevention of endometrial pathology in women with breast cancer treated with tamoxifen.Int. J. Med. 2010; 3: 327-330
Article info
Publication history
Published online: March 14, 2016
Accepted:
March 9,
2016
Received:
March 7,
2016
Identification
Copyright
© 2016 Elsevier Ireland Ltd. All rights reserved.
